ReviewAdvances in therapy2017

A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.

Kensei Tobinai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.